Ubiquigent Ltd., a drug discovery and development company, appointed Rishi Shah head of chemistry. With extensive expertise in heterobifunctional molecules, Shah will support Ubiquigent’s internal drug discovery and strategic partnerships in the design, discovery, and development of DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-targeting Chimeras (DUBTACs).

Shah joins Ubiquigent from GlaxoSmithKline where he led the development of multiple targeted protein degradation (TPD) programs across a range of therapeutic areas, in addition to the development of an orally bioavailable PROTAC platform, a bifunctional linker library, and the identification of novel E3 ligase ligands for use in TPD applications.
 

“Ubiquigent is at an exciting stage of its growth, with an evolving focus on DUBTAC design and development through the application of its comprehensive DUB-focused drug discovery platform,” said Shah. “I look forward to working alongside the Ubiquigent team to further advance its pipeline of novel DUB modulators, as well as its strategic partnerships with industry and academia, empowering therapeutic progress across the fields of protein degradation and stabilisation.”

Jason Mundin, CEO Ubiquigent, said, “I am thrilled to welcome Rishi to the Ubiquigent team. With almost a decade of experience in heterobifunctional design and biological assay development, Rishi’s expertise will be critical in the continued development of both internal and partner DUB-focused drug discovery programmes and will strengthen our therapeutic focus on DUBTACs.”